JD.Com Inc vs Johnson & Johnson — how do they compare? JD.Com Inc trades at $31.33 (market cap $44.04B), while Johnson & Johnson trades at $260.17 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 14.2× JD.Com Inc's market cap, and JD.Com Inc pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| JD | JNJ | |
|---|---|---|
Market Cap | $44.04B | $626.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $267.24 |
52-Week Low | $25.19 | $172.78 |
Enterprise Value | $30.10B | $654.37B |
Dividend Yield | 3.13% | 2.06% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
JD stock trades at $31.29, down 6.51% over 24 hours, amid broader pressure on Chinese equities. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue grew to $1.31 trillion in 2025. Technical indicators show a bullish overall signal, with RSI at 28.66 suggesting potential oversold conditions. Analyst consensus remains strongly bullish with a $38.00 price target.
The outlook is positive given earnings beats and low valuation multiples like P/S of 0.24, but risks include regulatory scrutiny from the EU over the Ceconomy deal and margin pressures from expansion costs. Upside potential exists if Q2 results on August 13, 2026, exceed expectations, though macroeconomic headwinds for Chinese stocks pose a near-term challenge.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Trailing returns across standard periods
Latest headlines on both assets
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →